HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
fazarabine
Also Known As:
1-beta-D-arabinosyl-5-azacytosine; 5-azacytosine arabinoside; NSC 281272; NSC-281272; ara-5-aza-Cyd; ara-5-azacytosine; ara-AC; arabinofuranosyl-5-azacytosine; arabinosyl-5-azacytosine
Networked:
31
relevant articles (
2
outcomes,
19
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Organic Chemicals: 133
Aza Compounds: 3
Azacitidine: 2073
fazarabine: 31
Heterocyclic Compounds: 198
1-Ring Heterocyclic Compounds
Pyrimidines: 510
Pyrimidine Nucleosides: 50
Cytidine: 535
Azacitidine: 2073
fazarabine: 31
Nucleic Acids, Nucleotides, and Nucleosides: 1
Nucleosides: 6847
Pyrimidine Nucleosides: 50
Cytidine: 535
Azacitidine: 2073
fazarabine: 31
Ribonucleosides: 49
Cytidine: 535
Azacitidine: 2073
fazarabine: 31
Related Diseases
1.
Leukemia
08/01/1999 - "
Based on this clinical and preclinical experience we designed a phase I study to determine the toxicity, maximum tolerated dose (MTD), and antileukemic efficacy of Fazarabine using a 3-day continuous infusion schedule in patients with refractory or relapsed acute leukemia or chronic myelogenous (CML) in blastic phase.
"
08/01/1999 - "
In conclusion, Fazarabine has not shown a beneficial effect in the therapy of acute leukemia.
"
08/01/1999 - "
Phase I study of arabinosyl-5-azacytidine (fazarabine) in adult acute leukemia and chronic myelogenous leukemia in blastic phase.
"
04/01/1995 - "
The cellular anabolism of ara-AC and DHAC and their effect on DNA methylation have been examined in two new human leukemia cell lines, which are sensitive (PER-145) and resistant (PER-163) to ara-C.
"
01/01/1989 - "
Ara-AC demonstrated marked antitumor activity against human tumor xenografts, including leukemias and solid tumors that do not respond to Ara-C or 5-AC.
"
2.
Carcinoma (Carcinomatosis)
02/01/1993 - "
Fazarabine: a report of response in a patient with multiply relapsed embryonal cell carcinoma.
"
09/01/1984 - "
The cytocidal activity of arabinosyl-5-azacytosine (araAC) and its effect on the synthesis and methylation of DNA in the human colon carcinoma cell line HT-29 was examined and compared with three other cytidine analogues.
"
02/01/1993 - "
This report describes a patient with multiply relapsed and advanced metastatic embryonal cell carcinoma who achieved a pathological partial remission (PR) following treatment with a Phase I chemotherapeutic agent, arabinosyl-5-azacytosine (Ara-AC), followed by orchiectomy.
"
09/01/1986 - "
Factors influencing the activity of the nucleoside analogue arabinosyl-5-azacytosine (ara-AC) were studied in P388 murine lymphoblasts in vitro and in vivo, in variants of these cells with artificially acquired resistance, in the naturally resistant colon 38 carcinoma in vivo, and in a panel of six human tumors maintained in continuous culture.
"
11/15/1990 - "
We evaluated the interaction of a biochemically active concentration of cyclopentenyl cytosine (CPE-C), an investigational antimetabolite which inhibits CTP synthetase, on the cytotoxicity of arabinosyl-5-azacytosine (Ara-AC) and 1-beta-D-arabinofuranosylcytosine (Ara-C) in HCT 116 colon carcinoma cells.
"
3.
Neoplasms (Cancer)
12/01/1997 - "
Phase II trials of Ara-AC in selected malignancies are planned.
"
11/01/1993 - "
A phase I trial of fazarabine in refractory pediatric solid tumors.
"
02/15/1991 - "
A phase I trial of fazarabine (ara-AC, 1-beta-D-arabinofuranosyl-5-azacytosine, NSC 281272) administered as a 24-h continuous infusion was performed in 24 adults with solid tumor malignancies.
"
09/15/1989 - "
A phase I trial of fazarabine (1-beta-D-arabinofuranosyl-5-azacytosine, NSC 281272) administered as a 24-h continuous infusion was performed in 16 children with refractory malignancies.
"
01/01/1989 - "
Studies on the activity of Ara-AC in these and other human tumor xenograft models were undertaken to define its potential anti-human-tumor profile more completely.
"
4.
Colonic Neoplasms (Colon Cancer)
02/01/1993 - "
Eighteen patients with refractory metastatic colon cancer were enrolled in a phase II trial of fazarabine.
"
02/01/1993 - "
Phase II study of fazarabine (NSC 281272) in patients with metastatic colon cancer.
"
07/05/1991 - "
We studied the cytotoxicity of arabinosyl-5-azacytosine (Ara-AC), a dCyd antagonist which inhibits DNA synthesis, in combination with 5-fluorouracil (FUra) in two human colon cancer cell lines, HCT 116 and SNU-C4.
"
5.
Adenocarcinoma
08/01/1992 - "
Phase II trial of fazarabine (arabinofuranosyl-5-azacytidine) in patients with advanced pancreatic adenocarcinoma.
"
08/01/1992 - "
We conducted a phase II evaluation of fazarabine 1.75-2.0 mg/m2/hr over 72 hours every 28 days in 14 previously untreated patients with advanced adenocarcinoma of the pancreas.
"
04/01/1992 - "
A total of 15 patients with measurable advanced colorectal adenocarcinoma were prospectively treated with fazarabine (Ara-AC), reconstituted in dimethyl sulfoxide, and administered at a starting dose of 48 mg/m2/day as a continuous intravenous infusion for three days.
"
Related Drugs and Biologics
1.
fazarabine
2.
Azacitidine (5 Azacytidine)
3.
Cytarabine (Cytosar-U)
4.
Nucleosides
5.
Antineoplastic Agents (Antineoplastics)
6.
Cytostatic Agents
7.
Granulocyte Colony-Stimulating Factor (G-CSF)
8.
Ancitabine
9.
pyrimidine
10.
Antimetabolites
Related Therapies and Procedures
1.
Orchiectomy (Orchidectomy)
2.
Therapeutics
3.
Intravenous Infusions
4.
Drug Therapy (Chemotherapy)